Clinical Trials Logo

Oncology clinical trials

View clinical trials related to Oncology.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06122857 Active, not recruiting - Cancer Clinical Trials

Trends of Cancer Incidence and Mortality in Russia

Start date: October 2, 2023
Phase:
Study type: Observational

The study aims to assess the dynamics of incidence and mortality for all major groups of cancers for which the national data is available for the longest possible time series. The data obtained from publicly available sources are used.

NCT ID: NCT06043947 Active, not recruiting - Breast Cancer Clinical Trials

Survival Monitoring in Russian Cancer Registries

SURVIMON
Start date: August 1, 2023
Phase:
Study type: Observational [Patient Registry]

This study aims to establish a holistic framework for continuous cancer survival surveillance in Russian regions with high-quality population-based cancer registry data. The data from the population-based cancer registries of the Northwestern regions of Russia will be used to assess net and cause-specific survival trends.

NCT ID: NCT06015009 Active, not recruiting - Oncology Clinical Trials

Symptom Management App for Children at the Early Stage of Cancer Survivorship and Their Caregivers

Start date: September 4, 2023
Phase: N/A
Study type: Interventional

This pilot trial aims to determine the feasibility, usability, acceptability, and preliminary effect of the symptom management mHealth app. Participants meeting the aforementioned criteria (section d(i)) will be eligible to participate.

NCT ID: NCT05842083 Active, not recruiting - Oncology Clinical Trials

On-site Supportive Communication Training in Doctor-patient Communication

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized, controlled clinical trial is to test a new concept for communication skills training (on-site supportive communication training (on-site SCT) in cancer care. The study aims to determine the impact of on-site SCT on patients' rating of oncologists' communication abilities. Oncologists participating in the study will be randomly allocated to the intervention or control group. In the intervention group each doctor will have a total of three intervention days at intervals of 3-4 weeks. On an intervention day, a psychologist will sit in and observe doctor-patient consultations. After the first consultations, 30 minutes are allocated for feedback to the doctor by the psychologist. After the last consultation of the day, 60 minutes are allocated for thorough feedback and establishment of learning goals to focus on until the next intervention day. Doctor's in the control group will conduct communication as usual. Researchers will compare the control and intervention groups to see if patients' rating of doctors' interpersonal and communication skills increase when the doctors have participated in on-site SCT. The 15-item Communication Assessment Tool (CAT) will be used. It will also be investigated whether on-site SCT increases the doctors' rating of themselves in relation to communication efficacy and job satisfaction and decrease their experience of burnout.

NCT ID: NCT05378139 Active, not recruiting - Cardiac Disease Clinical Trials

Continuous Wireless Monitoring of Vital Signs and Automated Alerts in Hospitalized Patients

Start date: February 1, 2021
Phase:
Study type: Observational

The primary aim of this study is to test and assess the implementation and effectiveness of continuous wireless vital signs monitoring with real-time alerts on: The frequency of patients monitored with adequate data quality as adequate clinical user satisfaction in the initial versus the last part of the trial (primary outcome).

NCT ID: NCT05237206 Active, not recruiting - Oncology Clinical Trials

Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies

Start date: April 28, 2022
Phase: Phase 1
Study type: Interventional

This Phase 1, first-in-human (FIH), open-label study is designed to assess the safety, tolerability, and preliminary clinical efficacy of repeated intravenous (IV) infusions of SUPLEXA monotherapy in subjects with measurable metastatic solid tumours and haematologic malignancies

NCT ID: NCT05122715 Active, not recruiting - Oncology Clinical Trials

Demonstration Of A Next Generation PET CT System

Start date: November 9, 2021
Phase: N/A
Study type: Interventional

The intent of this evaluation is to obtain user feedback on device performance, user preference, image quality, workflow, and new device features, a necessary part of product development. This study will also help to inform protocol development in reducing both scan time and/or radiologic tracer dose. The goal of this study is to collect a library of image data from the hybrid PET/CT system to be used for evaluation and optimization of the image quality of the system in a clinical setting and as comparison with the standard of care hybrid PET/CT system, Discovery MI 25m (DMI5R).

NCT ID: NCT05027165 Active, not recruiting - Oncology Clinical Trials

Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab

PRECISION
Start date: November 7, 2020
Phase:
Study type: Observational

This non-interventional single-center explorative biomarker study aims at longitudinal comprehensive characterization (molecular genetics, immunological, morphological, image-based and microbial features) of the patient (host) and tumor as well as changes during standard treatment and in case of recurrent disease in inoperable stage III non-small cell lung cancer (NSCLC). Comprehensive analysis will include peripheral blood cellular and humoral immunophenotyping, circulating tumor DNA and gut/saliva microbiota analyses. 18F-FDG-PET/CT before, 6 weeks, 6- and 12-months after chemoradiotherapy as well as daily in course of radiation treatment cone-beam-CT and/or MRI imaging are included for morphological analysis. This study will provide valuable information of predictive biomarkers in patients with stage III NSCLC treated with durvalumab maintenance treatment after concurrent chemoradiotherapy.

NCT ID: NCT04328818 Active, not recruiting - Sepsis Clinical Trials

Indwelling Device-associated Biofilms

BiofilmICU
Start date: June 5, 2019
Phase:
Study type: Observational [Patient Registry]

Healthcare associated infections linked to the use of indwelling medical devices increase hospital morbidity, mortality and the Intensive Care treatment costs. The essential strategy for mitigating these consequences are prompt source identifcation and control, with appropriate antimicrobial therapy initiation as soon as possible. Removing the source is one of the golden rule for infection control. Early identification of the responsible germs is the other major guiding element for the appropriate anti-infectious treatment. Despite multiple detection/identification methods, there are no clear recommendations for biofilm identification in clinical practice. The gold standard method is bacterial/fungal culturing, with disadvantages related to late results, especially for slow growing, fastidious germs or related to the existence of uncultivable strains. In order to obtain more sensitive, specific results and to increase the chances of better biofilm characterization, in the present study the investigators compare biofilm identification results obtained by standard cultivation methods with those by DNA amplification and next generation gene sequencing. The studied biofilm is associated to four criticallly ill oncological patients indwelling devices (endotracheal tube, central venous catheter, arterial catheter and urinary catheter).

NCT ID: NCT04025385 Active, not recruiting - Rehabilitation Clinical Trials

High-Intensity-Interval-Training in Geriatric Rehabilitation - A Feasibility Study

Start date: July 30, 2019
Phase: N/A
Study type: Interventional

Study with Patients (40-60 participants) above the age of 65. There will be a comparison of regular training on ergometer (10 trainings within 2 weeks, 40 min each) to high intensity interval training on ergometer (6 trainings within 2 weeks, 25 min each). At the beginning and at the end will be a spiroergometer to measure the individual limits and vO2max, which will be compared amongst the two groups. To receive a subjective feedback, there will be a series of questionnaires at the beginning, after one week and at the end. The goal of this study is to get more information about whether a HII-Training is feasible with elderly patients and whether they can profit form it.